With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.197638-83-8,1-Boc-4-(4-Formylphenyl)piperazine,as a common compound, the synthetic route is as follows.
Example 37Te/t-butyl 4-(4-(6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-3H-imidazo[4,5- ?>]pyridin-2-yl)phenyl)piperazine-1-carboxylateTo a mixture of 5-chloro-4-(4-(4-chlorobenzyl)piperazin-1-yl)-3-nitropyridin-2-amine (prepared as described in example 37 of PCT/GB2006/004854; 0.042 g, 0.11 mmol) and EtOH (7 mL) was added te/t-butyl 4-(4-formylphenyl)piperazine-1-carboxylate (0.039 g, 0.14 mmol) followed by a freshly prepared aqueous solution of Na2S2O4 (1 M; 0.44 mL, 0.44 mmol). The reaction mixture was stirred at 80 0C for 20 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was absorbed on silica gel, and the free-running powder was placed on a 10 g isolute silica column. Elution with ethyl acetate / dichloromethane (v:v; 1 :1), and then 2.5%
197638-83-8, As the paragraph descriping shows that 197638-83-8 is playing an increasingly important role.
Reference£º
Patent; CHROMA THERAPEUTICS LTD.; WO2009/1021; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics